Dr. Stephan Rau focuses his practice on mergers and acquisitions (M&A) transactions and regulatory advice in the health and life science sector. He is the head of the Firm’s Health Law Practice Group in Europe.

Show More


  • Advising on investments in the clinical lab, renal care, hospital, pharma, medical device, biotech, food and online pharmacy businesses
  • Structuring various outsourcing projects, such as joint ventures between one of the largest medical schools in Europe and a large public hospital carrier leading to the establishment of the largest European clinical lab
  • Challenging market entry barriers to dialysis service providers under the German system of determination of need of the statutory health insurance system

Show More


  • The Best Lawyers in Germany 2019Mergers & Acquisitions
  • Chambers Europe 2018Leading Individual, Band 1 for Healthcare in Germany
  • JUVE Handbook, frequently recommended lawyer for Corporate, M&A and Private Equity, and distinguished advisor for Health Services

Show More


  • German-American Lawyers’ Association
  • German Association of Corporate Law
  • International Bar Association, Health and Life Sciences Law Committee, Co-Chair

Show More


Humboldt University of Berlin, Dr. jur. (PhD), 2003
Higher Court of Appeal, Berlin, Second State Exam, 1998
University of Heidelberg, First State Exam, 1996
University of Paris-Dauphine, Maîtrise en Économie Appliquée, 1994
London School of Economics and Political Science, Master of Science in Government, 1993
IHK Wiesbaden, interpreter and translator for Russian, 1990

Show More

October 2015

Telemedicine in Germany - What Legal Changes Are Needed and What Are ...

April 30, 2015

Comparable Drugs in Price Negotiations Under Sec. 130b SGB V

November 2014

New Developments On Combating Corruption and Compliance In Healthcare

October 29, 2014

German Perspective on New EU Clinical Trials Regulation

June 18, 2014

Pricing for New Innovative Drugs – Public Payers Attempt New Approach

April 23, 2014

Legal Framework for Health Apps

February 26, 2014

Generic Drug and API Producers Deal with the Bolar Exemption

February 19, 2014

Yet another Health Reform and Seizure of Retiring Doctors' Practices

January 2014

Patent Expirations: Generic Drugs and Active Ingredient Producers from the Perspective of ...